ERBB2 ECD mutants bind TKIs

Stable Identifier
R-HSA-9665412
Type
Reaction [binding]
Species
Homo sapiens
Compartment
cytosol, plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
ERBB2 ECD mutants bind TKIs
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Comapred with the wild type ERBB2, ERBB2 G309E, ERBB2 S310F and ERBB2 S310Y are more sensitive to tyrosine kinase inhibitors lapatinib, neratinib and afatinib (Greulich et al. 2012). ERBB2 G309A was also responsive to lapatinib and neratinib (Bose et al. 2013).
Literature References
PubMed ID Title Journal Year
22908275 Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

Walker, SR, Greulich, H, Pho, NH, Banerji, S, Berger, AH, Lawrence, MS, Getz, G, Frank, D, Tanaka, KE, Chen, TH, Mani, DR, Liao, R, Imielinski, M, Winckler, W, Lee, SH, Meyerson, M, Hahn, WC, Wong, KK, Ambrogio, L, Kaplan, B, Cho, J, Mertins, P, Carr, SA, Jaffe, JD, Zhang, X, Eck, MJ, Yun, CH, Zhang, J

Proc. Natl. Acad. Sci. U.S.A. 2012
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Shen, W, Aronson, AB, Goel, N, Koboldt, DC, Li, S, Searleman, AC, Ma, CX, Ellis, MJ, Shen, D, Ding, L, Monsey, J, Mardis, ER, Kavuri, SM

Cancer Discov 2013
Participants
Input
Output
Participates
as an event of
Normal reaction
ERBB2 binds TKIs (Homo sapiens)
Functional status

Gain of function of ERBB2 ECD mutants:ERBIN:HSP90:CDC37 [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2019-10-30)
Reviewed
Bose, R  (2019-10-25)
Kancha, RK  (2019-11-03)
Krishna, A  (2019-10-25)
Created
Orlic-Milacic, M  (2019-10-30)
Cite Us!